Condurangoglykosid A
CAS: 11051-90-4
Ref. 3D-LAA05190
| 1mg | 364.00 € | ||
| 2mg | 517.00 € | ||
| 5mg | 801.00 € | ||
| 10mg | 1,160.00 € | ||
| 25mg | 2,087.00 € |
Product Information
- (3β,11α,12β,14β)-11-(Acetyloxy)-3-[(O-6-deoxy-3-O-methyl-β-<span class="text-smallcaps">D</smallcap>-allopyranosyl-(1→4)-O-2,6-dideoxy-3-O-methyl-β-<smallcap>D</smallcap>-arabino-hexopyranosyl-(1→4)-2,6-dideoxy-3-O-methyl-β-<smallcap>D</span>-ribo-hexopyranosyl)oxy]-14-hydroxy-12-[(1-oxo-3-phenyl-2-propen-1-yl)oxy]pregnan-20-one
- (3β,8xi,9xi,11α,12β,14β)-11-(acetyloxy)-3-{[6-deoxy-3-O-methyl-β-D-allopyranosyl-(1->4)-2,6-dideoxy-3-O-methyl-β-D-ribo-hexopyranosyl-(1->4)-2,6-dideoxy-3-O-methyl-β-D-ribo-hexopyranosyl]oxy}-14-hydroxy-20-oxopregnan-12-yl (2E)-3-phenylprop-2-enoate
- Condurango glycoside A
- Pregnan-20-one, 11-(acetyloxy)-3-[(O-6-deoxy-3-O-methyl-β-<span class="text-smallcaps">D</smallcap>-allopyranosyl-(1→4)-O-2,6-dideoxy-3-O-methyl-β-<smallcap>D</smallcap>-arabino-hexopyranosyl-(1→4)-2,6-dideoxy-3-O-methyl-β-<smallcap>D</span>-ribo-hexopyranosyl)oxy]-14-hydroxy-12-[(1-oxo-3-phenyl-2-propen-1-yl)oxy]-, (3β,11α,12β,14β)-
- Pregnan-20-one, 11-(acetyloxy)-3-[(O-6-deoxy-3-O-methyl-β-<span class="text-smallcaps">D</smallcap>-allopyranosyl-(1→4)-O-2,6-dideoxy-3-O-methyl-β-<smallcap>D</smallcap>-arabino-hexopyranosyl-(1→4)-2,6-dideoxy-3-O-methyl-β-<smallcap>D</span>-ribo-hexopyranosyl)oxy]-14-hydroxy-12-[(1-oxo-3-phenyl-2-propenyl)oxy]-, (3β,11α,12β,14β)-
Condurangoglykosid A is a natural product and an anticancer drug that has shown to be effective in the treatment of prostate cancer. This drug inhibits the growth of tumour cells by preventing necrosis factor from binding to the cell membrane, which prevents the release of cytochrome C from mitochondria. Condurangoglykosid A also protects liver cells from damage and death by inhibiting toxins that are released into the body during cancer treatment. Condurangoglykosid A also inhibits tumor growth by blocking nuclear factor kappa-light-chain-enhancer (NFκB) activation in cancer cells. This drug can be administered orally and has been shown to be safe for human use. It has been observed that Condurangoglykosid A may have an antitumor effect on cervical cancer cells, but this has not been confirmed yet.
Chemical properties
Technical inquiry about: 3D-LAA05190 Condurangoglykosid A
If you want to request a quotation or place an order, please instead add the desired products to your cart and then request a quotation or order from the cart. It is faster, cheaper, and you will be able to benefit from the available discounts and other advantages.
